BioPharma Credit - Edison Group

Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Sparks
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

Chosa

MCap

SEK50m

Last close

SEK0.95

▲ 0.25 (35.71%)

Metals One

MCap

GBP4m

Last close

GBP0.01

▲ 0.18 (19.44%)

Quadrise

MCap

GBP86m

Last close

GBP0.05

▲ 0.55 (12.66%)
Sectors
Sectors
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

Financial Director
Equity Research
Investor Relations
Contact us

Overview
Research
Thematics

Latest Insights

View More

Investment Companies |
Review

03.11.22

Biopharma Credit — A quality dividend play with FY22 yield of 12%

Investment Companies |
edison tv

29.09.22

BioPharma Credit – executive interview

Investment Companies |
Update

16.03.22

Biopharma Credit — New transaction of up to US$50m

Investment Companies |
Update

10.01.22

Biopharma Credit — Fully invested after recent transactions

Sector

Investment Companies

Review

Investment Companies

30.09.19

BioPharma Credit — New debt investment in OptiNose

Review

Investment Companies

03.06.19

BioPharma Credit — Debt and equity investment in BDSI

Review

Investment Companies

06.11.18

Biopharma Credit — Oversubscribed offering fuels further growth

Update

Investment Companies

17.05.18

Biopharma Credit — Leading lender in life sciences